(Q40378087)

20 September 2017

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection (English)

1 reference

20 September 2017

0 references

William D Chey

1

1 reference

20 September 2017

Grigorios I Leontiadis

series ordinal

2

1 reference

20 September 2017

Colin W Howden

series ordinal

3

1 reference

20 September 2017

Steven F Moss

series ordinal

4

1 reference

20 September 2017

language of work or name

English

0 references

publication date

10 January 2017

1 reference

The American Journal of Gastroenterology

20 September 2017

1 reference

20 September 2017

112

1 reference

20 September 2017

2

1 reference

20 September 2017

212-239

1 reference

https://scigraph.springernature.com/pub.10.1038/ajg.2016.563

20 September 2017

0 references

cites work

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Helicobacter pylori infection in children of Texas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

The incidence of Helicobacter pylori acquisition in children of a Canadian First Nations community and the potential for parent-to-child transmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Horizontal versus familial transmission of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Effect of sibling number in the household and birth order on prevalence of Helicobacter pylori: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Acquisition of Helicobacter pylori infection in early childhood: independent contributions of infected mothers, fathers, and siblings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Helicobacter pylori determination in non-municipal drinking water and epidemiological findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Helicobacter pylori infection in Ontario: prevalence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

The Prevalence of Helicobacter pylori Remains High in African American and Hispanic Veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Neighborhood socio-economic characteristics, African ancestry, and Helicobacter pylori sero-prevalence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Race, African ancestry, and Helicobacter pylori infection in a low-income United States population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Helicobacter pylori infection in Canadian and related Arctic Aboriginal populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Helicobacter pylori infection in pregnant women from a U.S.-Mexico border population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Disease manifestations of Helicobacter pylori infection in Arctic Canada: using epidemiology to address community concerns

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Helicobacter pylori: evidence-based review with a focus on immigrant populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Seroprevalence of Helicobacter pylori in New York City populations originating in East Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Helicobacter pylori infection in different generations of Hispanics in the San Francisco Bay Area

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

American College of Gastroenterology guideline on the management of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Second cancers and residual disease in patients treated for gastric mucosa-associated lymphoid tissue lymphoma by Helicobacter pylori eradication and followed for 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

The role of Helicobacter pylori eradication in the treatment of diffuse large B-cell and marginal zone lymphomas of the stomach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Helicobacter pylori Eradication for Prevention of Metachronous Recurrence after Endoscopic Resection of Early Gastric Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Helicobacter pylori Eradication on the Prevention of Metachronous Lesions after Endoscopic Resection of Gastric Neoplasm: A Meta-Analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Clinical trial: prolonged beneficial effect of Helicobacter pylori eradication on dyspepsia consultations - the Bristol Helicobacter Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Meta-analysis:Helicobacter pylori‘test and treat’ compared with empirical acid suppression for managing dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Helicobacter pylori infection in functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

21 January 2018

Gastroduodenal Disorders

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

American Gastroenterological Association Institute Guideline on the Role of Upper Gastrointestinal Biopsy to Evaluate Dyspepsia in the Adult Patient in the Absence of Visible Mucosal Lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Helicobacter pylori Infection in Gastroesophageal Reflux Disease in the Asian Countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol helicobacter project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Effect of Helicobacter pylori eradication on the outcome of reflux esophagitis and chronic gastritis in the elderly. A randomized, multicenter, eight-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

The effect of Helicobacter pylori infection and eradication in patients with gastro-oesophageal reflux disease: A parallel-group, double-blind, placebo-controlled multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Effect of Helicobacter pylori eradication on reflux esophagitis therapy: a multi-center randomized control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Guidelines for prevention of NSAID-related ulcer complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Survey of anaemia and Helicobacter pylori infection in adolescent girls in Suihua, China and enhancement of iron intervention effects by H. pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Effects of H pylori therapy on erythrocytic and iron parameters in iron deficiency anemia patients with H pylori-positive chronic gastristis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Helicobacter pylori eradication: novel therapy for immune thrombocytopenic purpura? A review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura-a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Non-gastrointestinal tract associations of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Effectiveness of Helicobacter pylori eradication in chronic urticaria: evidence-based analysis using the Grading of Recommendations Assessment, Development, and Evaluation system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Is Helicobacter pylori infection associated with glycemic control in diabetics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Review article: Associations between Helicobacter pylori and obesity--an ecological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Reduced risk of atopic disorders in adults with Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Is Helicobacter Pylori infection inversely associated with atopy? A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Inverse association of esophageal eosinophilia with Helicobacter pylori based on analysis of a US pathology database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Does Helicobacter pylori protect against eosinophilic esophagitis in children?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Case-control study of association of eosinophilic gastrointestinal disorders with Helicobacter pylori infection in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: the population-based Kalixanda study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Helicobacter pylori infection is associated with a reduced risk of developing eosinophilic oesophagitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Decreased risk of celiac disease in patients with Helicobacter pylori colonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Prolonged treatment duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Seven-day therapy for Helicobacter pylori in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

One-Day Quadruple Therapy Compared With 7-Day Triple Therapy for Helicobacter pylori Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Fluoroquinolone Sequential Therapy for Helicobacter pylori: A Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Smoking increases the treatment failure for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Review article: the global emergence of Helicobacter pylori antibiotic resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

U.S. outpatient antibiotic prescribing, 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

The cost-effectiveness of competing strategies for the prevention of recurrent peptic ulcer hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Second-line Helicobacter pylori Eradication: A Randomized Comparison of 1-week or 2-week Bismuth-containing Quadruple Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Heat shock proteins in pancreatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Efficacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Second‐line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Review article: rifabutin in the treatment of refractory Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Current role of acid suppressants in Helicobacter pylori eradication therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Penicillin allergy: optimizing diagnostic protocols, public health implications, and future research needs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Current Status and Prospects for a Helicobacter pylori Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

A new highly effective short-term therapy schedule for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Epidemiology of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

High risk of failing eradication of Helicobacter pylori in patients with diabetes: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.563

Rescue Therapy with a Proton Pump Inhibitor Plus Amoxicillin and Rifabutin for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis

21 January 2018

1 reference

12 December 2020

Helicobacter pylori infection

1 reference

12 December 2020

Helicobacter pylori eradication for Parkinson's disease

1 reference

12 December 2020

Diagnosis of Helicobacter pylori after triple therapy in uncomplicated duodenal ulcers-a cost-effectiveness analysis

1 reference

12 December 2020

Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach

1 reference

12 December 2020

Initial management strategies for dyspepsia

1 reference

12 December 2020

Does H. pylori eradication therapy benefit patients with hepatic encephalopathy?: systematic review

1 reference

12 December 2020

Barrett's oesophagus: Evidence from the current meta-analyses.

1 reference

12 December 2020

Eradication of Helicobacter pylori Does Not Reduce the Incidence of Gastroduodenal Ulcers in Patients on Long-term NSAID Treatment: Double-Blind, Randomized, Placebo-Controlled Trial

1 reference

12 December 2020

Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials

1 reference

12 December 2020

One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease

1 reference

12 December 2020

ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and

1 reference

12 December 2020

Antimicrobial susceptibility of Canadian isolates of Helicobacter pylori in Northeastern Ontario

1 reference

12 December 2020

Bismuth-based triple therapy with bismuth subcitrate, metronidazole and tetracycline in the eradication of Helicobacter pylori: a randomized, placebo controlled, double-blind study

1 reference

12 December 2020

Appropriate timing of the 14C-urea breath test to establish eradication of Helicobacter pylori infection

1 reference

12 December 2020

Eradication of Helicobacter pylori for non-ulcer dyspepsia

1 reference

12 December 2020

Helicobacter pylori Infection Is Associated with an Increased Risk of Hyperemesis Gravidarum: A Meta-Analysis

1 reference

12 December 2020

Discontinuation rates of Helicobacter pylori treatment regimens: a meta-analysis

1 reference

12 December 2020

High prevalence of Helicobacter pylori in the Alaska native population and association with low serum ferritin levels in young adults

1 reference

12 December 2020

Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered?

1 reference

12 December 2020

Helicobacter pylori-associated ulcer bleeding: should we test for eradication after treatment?

1 reference

12 December 2020

Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis

1 reference

12 December 2020

Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patien

1 reference

12 December 2020

Epidemiology of Helicobacter pylori infection

1 reference

12 December 2020

Changing Patterns of Helicobacter pylori Gastritis in Long-Standing Acid Suppression

1 reference

12 December 2020

Hyperendemic H. pylori and tapeworm infections in a U.S.-Mexico border population.

1 reference

12 December 2020

Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies

1 reference

12 December 2020

Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy

1 reference

12 December 2020

Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy

1 reference

12 December 2020

The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study

1 reference

12 December 2020

Helicobacter pylori infection and gender: a meta-analysis of population-based prevalence surveys

1 reference

12 December 2020

Factors influencing the eradication of Helicobacter pylori with triple therapy

1 reference

12 December 2020

Optimum duration of regimens for Helicobacter pylori eradication

1 reference

12 December 2020

Helicobacter pylori eradication in dyspeptic primary care patients: a randomized controlled trial of a pharmacy intervention.

1 reference

12 December 2020

Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy

1 reference

12 December 2020

Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy

1 reference

12 December 2020

Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia

1 reference

12 December 2020

Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication

1 reference

12 December 2020

Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers

1 reference

12 December 2020

Efficacy of Helicobacter pylori eradication on platelet recovery in children with chronic idiopathic thrombocytopenic purpura

1 reference

12 December 2020

Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection

1 reference

12 December 2020

Identifiers

DOI

10.1038/AJG.2016.563

1 reference

Dimensions Publication ID

20 September 2017

0 references

1 reference